In this context, we report that EPO prevents the alterations induced by MPP+ in mitochondrial morphology and fuels the glycolytic process to compensate for the loss of activity of mitochondrial complex I. We also show the therapeutic efficacy of EPO in a murine model of PD, describing that EPO improves the behavioral outcome and the recovery of dopaminergic markers. Here, EPO is linked to Parkinson disease.